X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The fundings will advance the development of Ensoma’s Engenious™ in vivo engineered cell therapy platform and pipeline of genomic medicines for immuno-oncology, genetic disease and other therapeutic applications.
Lead Product(s): Genomic Medicine
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Kite Pharma
Deal Size: $135.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing May 16, 2023
Details:
The company’s Engenious™ platform combines innovative delivery technology with the full DNA editing toolkit to tackle diseases that affect millions around the world, such as cancer and autoimmune disease, as well as inherited conditions.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Cell and Gene therapy
Recipient: Twelve Bio
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition February 09, 2023
Details:
Company’s Engenious™ vectors Delivered without Stem Cell Collection or Myeloablative Conditioning in Outpatient and Low-Resource Settings, Enabling Access Worldwide.
Lead Product(s): Engenious vectors,HSC gene therapy
Therapeutic Area: Rare Diseases and Disorders Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: 5AM Ventures
Deal Size: $70.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing February 11, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
